SMC unable to recommend dexamethasone (Ozurdex ®) intravitreal implant due to absence of submission

Source: Scottish Medicines Consortium (SMC)

Date published: 17/01/2012 14:17

Summary
by: Nicola Pocock

The Scottish Medicines Consortium (SMC) is unable to recommend the use of dexamethasone (Ozurdex ®) 0.7mg intravitreal implant within NHS Scotland for the treatment of adult patients with inflammation of the posterior segment of the eye presenting as non-infectious uveitis, as the holder of the marketing authorisation has not made a submission.

Preview your comment

Add new comment

Comment text:

Comments

There are no comments yet. You could be the first! You must be Logged In to comment.